Hematologic malignancies
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Eligibility criteria: 1 Patients who were first diagnosed with acute leukemia in our center, including acute myeloid leukemia and acute lymphoblastic leukemia, had indications for transplantation, were eligible for physical examination, and planned to undergo haploidentical hematopoietic stem cell transplantation after induction chemotherapy, regardless of sex, aged 18-50 years old; 2KPS score >60 points, predicted survival time >6 months; 3 without serious damage of vital organs: 1) creatinine =2g/dl; 3) cardiac ejection index >55%; 4) heme >9g/dL, bilirubin < 2.0mg/dl; 4 no contraindication of hematopoietic stem cell transplantation; 5 Voluntarily participated in this study and signed the informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1 Active bleeding due to medication or low platelet count; 2 Pregnant or breastfeeding women; 3 Patients with other malignant tumors that require treatment; 4 Patients with clinical symptoms of cerebral dysfunction or severe psychiatric disorders that prevent understanding or compliance with the study protocol; 5 Patients with a history of severe acute allergic reactions; 6 Uncontrolled active infections; 7 Uncontrolled severe diabetes, autoimmune diseases, severe hypertension, and other serious illnesses; 8 Insufficient residual bone marrow blood/peripheral blood samples from the subject's routine bone marrow aspiration, less than 2ml; 9 Patients deemed unsuitable for clinical trials by the researchers for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 100-day incidence rate of aGVHD;1-year incidence rate of cGVHD; | — |
Countries
China
Contacts
The Second Affiliated Hospital of Army Medical University